ReviewClinical and molecular hepatology2024
Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury.
Review in Clinical and molecular hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Effects of Normothermic Hepatic Ischemia-Reperfusion Injury on the Hepatic Disposition of Arachidonic Acid and Its Cytochrome P450-Generated Metabolites in Rats.Pharmaceutical research · 2026Article
- Inflammatory gut-liver crosstalk: mechanisms and therapeutic targets.Experimental & molecular medicine · 2026Review
- The emerging role of neutrophil extracellular traps in liver diseases: a narrative review.Medical molecular morphology · 2026Review
- Mitophagy in Hepatic Ischemia-Reperfusion Injury: From Mitochondrial Dysfunction to Therapeutic Targeting.Biomolecules · 2026Review
- Preconditioning with sufentanil confers protective effects in transplantation by attenuating hepatic ischemia-reperfusion injury.World journal of transplantation · 2026Review
- SAA/FPR2 Signaling Between Pericentral Hepatocytes and Macrophages Exacerbates Zonated Liver Transplant Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Neutrophils and Neutrophil Extracellular Traps in Hepatic Ischemia-Reperfusion Injury: Molecular Mechanisms and Therapeutic Strategies.International journal of molecular sciences · 2026Review
- HSP90AA1 inhibits the Jun/Fos pathway to rescue hepatocytes from cuproptosis during ischemia-reperfusion injury.Clinical and experimental medicine · 2026Article
- Btg2 inhibits Fmo1 UFMylation thus exacerbating ferroptosis and apoptosis in hepatic ischemia-reperfusion injury.Nature communications · 2026Article
- Rutin as a Potential Therapeutic Agent for Multi-Organ Ischemia-Reperfusion Injury: From Multidimensional Mechanisms to Clinical Translation.Molecules (Basel, Switzerland) · 2026Review
- Identification of key genes in the pathogenesis of hepatic ischemia-reperfusion injury based on bioinformatics and experimental verification.Scientific reports · 2026Article
- Protective effect of ischemic preconditioning against hepatic ischemia-reperfusion injury and associated remote organ damage.World journal of gastrointestinal surgery · 2026Review
- Acute Stress Attenuates Hepatic Ischemia-Reperfusion Injury via Hypothalamic CRH Neuron-Induced HPA Axis Activation.CNS neuroscience & therapeutics · 2026Article
- Novel strategies for mitigating hepatic ischemia-reperfusion injury: targeting MICU1 and calcium-glycolytic homeostasis with acteoside.International journal of biological sciences · 2026Article
- Ursolic acid mitigates hepatic ischemia-reperfusion injury by regulating the ALOX12/12(S)-HETE and PTGES/prostaglandin E2 axis via arachidonic acid metabolism pathway.Frontiers in pharmacology · 2026Article
- Advances in basic research on post-cardiac arrest syndrome in adults: a comprehensive review.Frontiers in medicine · 2026Review
- Nicotinic acid protects against hepatic ischemia-reperfusion injury via suppressing mitochondrial damage-induced ferroptosis.Liver research (Beijing, China) · 2025Article
- Protective effects of treprostinil and ischemic preconditioning on hepatic ischemia-reperfusion injury and biomarkers in experimental studies in rats.World journal of gastrointestinal surgery · 2025Article
- Transcriptomic exploration combined with experimental validation: uncovering the potential value of biomarkers related to ammonia-induced cell death in hepatic ischemia-reperfusion injury.European journal of medical research · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatic ischemia‒reperfusion injury (HIRI) is a common and inevitable complication of hepatic trauma, liver resection, or liver transplantation. It contributes to postoperative organ failure or tissue rejection, eventually affecting patient prognosis and overall survival. The pathological mechanism of HIRI is highly complex and has not yet been fully elucidated. The proposed underlying mechanisms include mitochondrial damage, oxidative stress imbalance, abnormal cell death, immune cell hyperactivation, intracellular inflammatory disorders and other complex events. In addition to serious clinical limitations, available antagonistic drugs and specific treatment regimens are still lacking. Therefore, there is an urgent need to not only clarify the exact etiology of HIRI but also reveal the possible reactions and bottlenecks of existing drugs, helping to reduce morbidity and shorten hospitalizations. We analyzed the possible underlying mechanism of HIRI, discussed various outcomes among different animal models and explored neglected potential therapeutic strategies for HIRI treatment. By thoroughly reviewing and analyzing the literature on HIRI, we gained a comprehensive understanding of the current research status in related fields and identified valuable references for future clinical and scientific investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.